Skip to main content

Table 2 Charlson comorbidity index in treatment and control groups (M ± SD or number of cases)

From: Efficacy of the Essential Amino Acids and Keto-Analogues on the CKD progression rate in real practice in Russia - city nephrology registry data for outpatient clinic

 

Treatment group

Control group

p

Charlson comorbidity index

4,91 ± 1,67

5,09 ± 1,58

0,59

Myocardial infarction

8

9

0,73

Congestive heart failure

24

28

0,37

Peripheral disease

43

36

0,14

Cerebrovascular disease

28

24

0,35

Dementia

3

6

0,21

Chronic pulmonary disease

9

13

0,23

Connective tissue disease

2

5

0,17

Peptic ulcer disease

13

19

0,12

Mild liver disease

11

18

0,07

Diabetes without end-organ damage

10

11

0,75

Hemiplegia

4

2

0,15

Moderate or severe renal disease

96

96

Diabetes with end-organ damage

2

3

0,56

Tumor without metastasis

4

3

0,61

Leukemia

1

1

Lymphoma

1

1

Moderate or severe liver disease

3

4

0,61

Metastatic solid tumor

0

0

AIDS

0

0